Home / Oncology Nursing / Insys Event

Insys Event

Insys_Email_Banner

Breakthrough Cancer Pain (BTCP): Key Insights from Patients

This presentation will include disease state information on breakthrough cancer pain, its management and insights from patients about their cancer pain journey.

THIS IS NOT A CME/CEU EVENT. Consistent with PhRMA guidelines, spouses and guests will not be permitted to attend industry-sponsored events. We appreciate your support and thank you in advance for your cooperation. INSYS Therapeutics is required to disclose all items of value provided to healthcare providers. By attending the speaker program, you are accepting the disclosure of the cost of the meal. 

When:

Thursday, October 12, 2017

Northern NJ

Maggiano’s Little Italy
70 Riverside Square
Hackensack, NJ 07601
Sheila Ayers, RN, BSN, MSN, ACNP-BC
The West Cancer Clinic, Germantown, TN
Wednesday, October 18, 2017

Dallas

Trulucks
2401 McKinney Avenue
Dallas, Tx 75201
Connie Ferraro, RN, BSN, OCN
Northern Ohio Regional Cancer Center, OH
Thursday, November 2, 2017

Boston, MA

Smith and Wollensky
294 Congress St.
Boston, MA 02210
Sheila Ayers, RN, BSN, MSN, ACNP-BC
The West Cancer Clinic, Germantown, TN

 

Selected Important Safety Information

IMPORTANCE OF PROPER PATIENT SELECTION, DOSING, and POTENTIAL FOR ABUSE

TIRF medicines contain fentanyl, an opioid agonist and a Schedule II controlled substance, with an abuse liability similar to other opioid analgesics. TIRF medicines can be abused in a manner similar to other opioid agonists, legal or illicit. Consider the potential for abuse when prescribing or dispensing TIRF medicines in situations where the physician or pharmacist is concerned about an increased risk of misuse, abuse or diversion. Schedule II opioid substances that include morphine, oxycodone, hydromorphone, oxymorphone, and methadone have the highest potential for abuse and risk of fatal overdose due to respiratory depression.

Serious adverse events, including deaths, in patients treated with some oral transmucosal fentanyl medicines have been reported. Deaths occurred as a result of improper patient selection (e.g., use in opioid non-tolerant patients) and/or improper dosing. The substitution of a TIRF medicine for any other fentanyl medicine, including another TIRF medicine, may result in fatal overdose.

TIRF medicines are indicated only for the management of breakthrough pain in adult cancer patients 18 years of age and older (16 years of age and older for Actiq® brand and generic equivalents) who are already receiving and who are tolerant to around-the- clock opioid therapy for their underlying persistent cancer pain.

Patients considered opioid-tolerant are those who are taking:

  • at least 60 mg of oral morphine daily
  • at least 25 mcg transdermal fentanyl/hour
  • at least 30 mg of oral oxycodone daily
  • at least 8 mg oral hydromorphone daily
  • at least 25 mg oral oxymorphone daily
  • at least 60 mg oral hydrocodone daily
  • or an equianalgesic dose of another opioid daily for a week or longer.

TIRF medicines are contraindicated in opioid non-tolerant patients and are contraindicated in the management of acute or postoperative pain, including headache/migraine and dental pain, or in the emergency department. Please see the individual medicine prescribing information for a full list of specific situations in which TIRF medicines are not indicated or are contraindicated. Life-threatening respiratory depression could occur at any dose in opioid non-tolerant patients or in opioid-tolerant patients when used as recommended. Deaths have occurred in opioid non-tolerant patients treated with some TIRF medicines.

When prescribing, do not convert patients on a mcg per mcg basis from another fentanyl medicine to a TIRF medicine, except for substitutions between a branded TIRF medicine and its generic equivalent. Patients beginning treatment with TIRF medicines must begin with titration from the lowest available dose for that specific medicine. Carefully consult the Initial Dosing Instructions in the TIRF medicine-specific Full Prescribing Information.

When dispensing, TIRF medicines are not interchangeable with each other, regardless of route of administration. Differences exist in the pharmacokinetics of TIRF medicines resulting in clinically important differences in the amount of fentanyl absorbed that could cause a fatal overdose. Converting patients from one TIRF medicine to a different TIRF medicine must not be done on a microgram-per-microgram basis, and must be titrated according to the labeled dosing instructions each time they begin use of a new TIRF medicine. The only exception is for substitution between a branded TIRF medicine and its specific generic equivalent.

Special care must be used when dosing TIRF medicines. Refer to the Full Prescribing Information for the individual TIRF medicine for guidance on the maximum number of doses that can be taken per breakthrough pain episode and the time that patients must wait before treating another episode of breakthrough pain with the TIRF medicine.

TIRF medicines are intended to be used only in the care of opioid-tolerant cancer patients and only by healthcare professionals who are knowledgeable of, and skilled in, the use of Schedule II opioids to treat cancer pain.

Patients and their caregivers must be instructed that TIRF medicines contain a medicine in an amount that can be fatal in children, in individuals for whom it is not prescribed, and in those who are not opioid-tolerant. All medicines must be kept out of the reach of children.

The concomitant use of TIRF medicines with cytochrome P450 3A4 inhibitors may result in an increase in fentanyl plasma concentrations, and may cause potentially fatal respiratory depression. Similarly, when CYP3A4 inhibitors are discountinued, fentanyl plasma concentrations may increase, prolonging adverse reactions. 

Adverse Reactions

The most commonly observed adverse reactions with TIRF medicines include typical opioid adverse reactions, such as nausea, vomiting, constipation, somnolence, dizziness, and headache. Refer to individual medicine prescribing information for all adverse reactions.
Expect opioid side effects and manage them accordingly.

Please see the individual Full Prescribing Information for each TIRF medicine for all information including boxed warnings, and Medication Guide for important safety information for each TIRF medicine.

Adverse Event Reporting

Promptly report suspected adverse events including misuse, abuse, addiction and overdoses directly to the TIRF REMS Access program at 1-866-822-1483. You also may report adverse event information to the FDA MedWatch Reporting System by telephone at 1-800-FDA-1088 or by mail using Form 3500, available at www.fda.gov/medwatch.

Medication Guide
It is important that you discuss the risks of TIRF medicines with your patients and encourage them to read the relevant Medication Guide. The Medication Guide provides important information on the safe and effective use of TIRF medicine and you will need to review the appropriate Medication Guide for the TIRF medicines you prescribe to your patient. Patients should be counseled on the need to store TIRF medicines safely out of the reach of children and other persons for whom the medicine is not prescribed.

You must provide your patient with a copy of the appropriate Medication Guide for the TIRF medicine you prescribe. Medication Guides will be provided to you by the manufacturers of individual TIRF medicines. If you require additional Medication Guides you can:

  • Print copies from the TIRF REMS Access program website at www.TIRFREMSaccess.com.
  • Contact the TIRF REMS Access program at 1-866-822-1483.
AMC2015_Logo   INSYS-LOGO-60pct-Gray-Dot

 

© 2017 INSYS Therapeutics, Inc. All rights reserved.  SUB-XX-XXXXX  July 2017